Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Arthritis Research & Therapy
Published in: Arthritis Research & Therapy 1/2009

Open Access 01-02-2009 | Research article

Increased expression of FcγRI/CD64 on circulating monocytes parallels ongoing inflammation and nephritis in lupus

Authors: Yi Li, Pui Y Lee, Eric S Sobel, Sonali Narain, Minoru Satoh, Mark S Segal, Westley H Reeves, Hanno B Richards

Published in: Arthritis Research & Therapy | Issue 1/2009

Login to get access

Abstract

Introduction

The high-affinity receptor for IgG Fcγ/CD64 is critical for the development of lupus nephritis (LN). Cross-linking Fc receptor on recruited monocytes by IgG-containing immune complexes is a key step in immune-complex-mediated nephritis in systemic lupus erythematosus (SLE). The goal of this study was to determine whether expression of Fc receptor (FcγR) I on circulating monocytes is associated with systemic inflammation and renal disease in SLE patients.

Methods

We studied 205 SLE patients (132 with LN and 73 without LN) along with 74 healthy control individuals. Surface expression of CD14 (monocytes), FcγRI/CD64, FcγRII/CD32, and FcγRIII/CD16 was evaluated by flow cytometry. Monocyte function was assessed by determining the migratory capacity and the ability to produce CCL2 (monocyte chemotractic protein 1). High-sensitivity C-reactive protein, C3 and C4 were measured by nephelometry.

Results

There was little difference in the expression of FcγRIII/CD16 or FcγRIII/CD32 on circulating monocytes between patients with SLE and control individuals. In contrast, FcγRI/CD64 expression was significantly higher in SLE patients and even higher in patients with LN. FcγRI/CD64 expression was positively associated with serum creatinine and indicators of systemic inflammation. Monocytes from patients with high FcγRI/CD64 expression also exhibited increased chemotaxis and capacity to produce monocyte chemotractic protein 1.

Conclusions

Increased FcγRI/CD64 expression on circulating monocytes parallels systemic inflammation and renal disease in SLE patients. We propose that circulating monocytes activated by immune complexes and/or proinflammatory mediators upregulate surface expression of FcγRI/CD64 in SLE. The enhanced chemotactic and inflammatory potential of the activated monocytes may participate in a vicious cycle of immune cell recruitment and renal injury in SLE.
Appendix
Available only for authorised users
Literature
1.
Reeves WH, Narain S, Satoh M: Autoantibodies in systemic lupus erythematosus. Arthritis and Allied Conditions. Edited by: Koopman WJ, Moreland LW. 2004, Philadelphia, PA: Lippincott Williams & Wilkins, 1497-1521.
2.
Lukacs K, Kavai M, Banyai A, Sonkoly I, Vegh E, Szabo G, Szegedi G: Effects of immune complexes from SLE patients on human monocyte locomotion and Fc receptor function. Ann Rheum Dis. 1984, 43: 729-733. 10.1136/ard.43.5.729.PubMedCentralCrossRefPubMed
3.
McLigeyo SO: Pathogenesis of lupus nephritis: a review. East Afr Med J. 1998, 75: 628-631.PubMed
4.
Rovin BH, Song H, Birmingham DJ, Hebert LA, Yu CY, Nagaraja HN: Urine chemokines as biomarkers of human systemic lupus erythematosus activity. J Am Soc Nephrol. 2005, 16: 467-473. 10.1681/ASN.2004080658.CrossRefPubMed
5.
Li Y, Tucci M, Narain S, Barnes EV, Sobel ES, Segal MS, Richards HB: Urinary biomarkers in lupus nephritis. Autoimmun Rev. 2006, 5: 383-388. 10.1016/j.autrev.2005.10.006.CrossRefPubMed
6.
Salmon JE, Pricop L: Human receptors for immunoglobulin G: key elements in the pathogenesis of rheumatic disease. Arthritis Rheum. 2001, 44: 739-750. 10.1002/1529-0131(200104)44:4<739::AID-ANR129>3.0.CO;2-O.CrossRefPubMed
7.
Ziegler-Heitbrock L: The CD14+ CD16+ blood monocytes: their role in infection and inflammation. J Leukoc Biol. 2007, 81: 584-592. 10.1189/jlb.0806510.CrossRefPubMed
8.
Pricop L, Redecha P, Teillaud JL, Frey J, Fridman WH, Sautes-Fridman C, Salmon JE: Differential modulation of stimulatory and inhibitory Fcγ receptors on human monocytes by Th1 and Th2 cytokines. J Immunol. 2001, 166: 531-537.CrossRefPubMed
9.
Ravetch JV, Bolland S: IgG Fc receptors. Annu Rev Immunol. 2001, 19: 275-290. 10.1146/annurev.immunol.19.1.275.CrossRefPubMed
10.
Clynes R, Dumitru C, Ravetch JV: Uncoupling of immune complex formation and kidney damage in autoimmune glomerulonephritis. Science. 1998, 279: 1052-1054. 10.1126/science.279.5353.1052.CrossRefPubMed
11.
Muller Kobold AC, Kallenberg CG, Tervaert JW: Monocyte activation in patients with Wegener's granulomatosis. Ann Rheum Dis. 1999, 58: 237-245. 10.1136/ard.58.4.237.CrossRefPubMed
12.
Wijngaarden S, van Roon JA, Bijlsma JW, Winkel van de JG, Lafeber FP: Fcγ receptor expression levels on monocytes are elevated in rheumatoid arthritis patients with high erythrocyte sedimentation rate who do not use anti-rheumatic drugs. Rheumatology (Oxford). 2003, 42: 681-688. 10.1093/rheumatology/keg174.CrossRef
13.
Fries LF, Mullins WW, Cho KR, Plotz PH, Frank MM: Monocyte receptors for the Fc portion of IgG are increased in systemic lupus erythematosus. J Immunol. 1984, 132: 695-700.PubMed
14.
Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, Schaller JG, Talal N, Winchester RJ: The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982, 25: 1271-1277. 10.1002/art.1780251101.CrossRefPubMed
15.
Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH: Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum. 1992, 35: 630-640. 10.1002/art.1780350606.CrossRefPubMed
16.
Barnes EV, Narain S, Naranjo A, Shuster J, Segal MS, Sobel ES, Armstrong AE, Santiago BE, Reeves WH, Richards HB: High sensitivity C-reactive protein in systemic lupus erythematosus: relation to disease activity, clinical presentation and implications for cardiovascular risk. Lupus. 2005, 14: 576-582. 10.1191/0961203305lu2157oa.CrossRefPubMed
17.
Sjowall C, Bengtsson AA, Sturfelt G, Skogh T: Serum levels of autoantibodies against monomeric C-reactive protein are correlated with disease activity in systemic lupus erythematosus. Arthritis Res Ther. 2004, 6: R87-R94. 10.1186/ar1032.PubMedCentralCrossRefPubMed
18.
Lloyd CM, Minto AW, Dorf ME, Proudfoot A, Wells TN, Salant DJ, Gutierrez-Ramos JC: RANTES and monocyte chemoattractant protein-1 (MCP-1) play an important role in the inflammatory phase of crescentic nephritis, but only MCP-1 is involved in crescent formation and interstitial fibrosis. J Exp Med. 1997, 185: 1371-1380. 10.1084/jem.185.7.1371.PubMedCentralCrossRefPubMed
19.
Kelley VR: Leukocyte–renal epithelial cell interactions regulate lupus nephritis. Semin Nephrol. 2007, 27: 59-68. 10.1016/j.semnephrol.2006.09.008.CrossRefPubMed
20.
Tucci M, Barnes EV, Sobel ES, Croker BP, Segal MS, Reeves WH, Richards HB: Strong association of a functional polymorphism in the monocyte chemoattractant protein 1 promoter gene with lupus nephritis. Arthritis Rheum. 2004, 50: 1842-1849. 10.1002/art.20266.CrossRefPubMed
21.
Marnell L, Mold C, Du Clos TW: C-reactive protein: ligands, receptors and role in inflammation. Clin Immunol. 2005, 117: 104-111. 10.1016/j.clim.2005.08.004.CrossRefPubMed
22.
Bang R, Marnell L, Mold C, Stein MP, Clos KT, Chivington-Buck C, Clos TW: Analysis of binding sites in human C-reactive protein for Fc{γ}RI, Fc{γ}RIIA, and C1q by site-directed mutagenesis. J Biol Chem. 2005, 280: 25095-25102. 10.1074/jbc.M504782200.CrossRefPubMed
23.
Tron K, Manolov DE, Rocker C, Kachele M, Torzewski J, Nienhaus GU: C-reactive protein specifically binds to Fcγ receptor type I on a macrophage-like cell line. Eur J Immunol. 2008, 38: 1414-1422. 10.1002/eji.200738002.CrossRefPubMed
24.
Sumegi A, Antal-Szalmas P, Aleksza M, Kovacs I, Sipka S, Zeher M, Kiss E, Szegedi G: Glucocorticosteroid therapy decreases CD14-expression and CD14-mediated LPS-binding and activation of monocytes in patients suffering from systemic lupus erythematosus. Clin Immunol. 2005, 117: 271-279. 10.1016/j.clim.2005.09.002.CrossRefPubMed
25.
Park SY, Ueda S, Ohno H, Hamano Y, Tanaka M, Shiratori T, Yamazaki T, Arase H, Arase N, Karasawa A, Sato S, Ledermann B, Kondo Y, Okumura K, Ra C, Saito T: Resistance of Fc receptor-deficient mice to fatal glomerulonephritis. J Clin Invest. 1998, 102: 1229-1238. 10.1172/JCI3256.PubMedCentralCrossRefPubMed
26.
Bergtold A, Gavhane A, D'Agati V, Madaio M, Clynes R: FcR-bearing myeloid cells are responsible for triggering murine lupus nephritis. J Immunol. 2006, 177: 7287-7295.CrossRefPubMed
27.
Parris TM, Kimberly RP, Inman RD, McDougal JS, Gibofsky A, Christian CL: Defective Fc receptor-mediated function of the mononuclear phagocyte system in lupus nephritis. Ann Intern Med. 1982, 97: 526-532.CrossRefPubMed
28.
Salmon JE, Millard S, Schachter LA, Arnett FC, Ginzler EM, Gourley MF, Ramsey-Goldman R, Peterson MG, Kimberly RP: FcγRIIA alleles are heritable risk factors for lupus nephritis in African Americans. J Clin Invest. 1996, 97: 1348-1354. 10.1172/JCI118552.PubMedCentralCrossRefPubMed
29.
Lin Q, Xiu Y, Jiang Y, Tsurui H, Nakamura K, Kodera S, Ohtsuji M, Ohtsuji N, Shiroiwa W, Tsukamoto K, Amano H, Amano E, Kinoshita K, Sudo K, Nishimura H, Izui S, Shirai T, Hirose S: Genetic dissection of the effects of stimulatory and inhibitory IgG Fc receptors on murine lupus. J Immunol. 2006, 177: 1646-1654.CrossRefPubMed
30.
Salmon JE, Kimberly RP, Gibofsky A, Fotino M: Defective mononuclear phagocyte function in systemic lupus erythematosus: dissociation of Fc receptor-ligand binding and internalization. J Immunol. 1984, 133: 2525-2531.PubMed
31.
Hepburn AL, Mason JC, Davies KA: Expression of Fcγ and complement receptors on peripheral blood monocytes in systemic lupus erythematosus and rheumatoid arthritis. Rheumatology (Oxford). 2004, 43: 547-554. 10.1093/rheumatology/keh112.CrossRef
32.
Mackay M, Stanevsky A, Wang T, Aranow C, Li M, Koenig S, Ravetch JV, Diamond B: Selective dysregulation of the FcγIIB receptor on memory B cells in SLE. J Exp Med. 2006, 203: 2157-2164. 10.1084/jem.20051503.PubMedCentralCrossRefPubMed
33.
Dijstelbloem HM, Bijl M, Fijnheer R, Scheepers RH, Oost WW, Jansen MD, Sluiter WJ, Limburg PC, Derksen RH, Winkel van de JG, Kallenberg CG: Fcγ receptor polymorphisms in systemic lupus erythematosus: association with disease and in vivo clearance of immune complexes. Arthritis Rheum. 2000, 43: 2793-2800. 10.1002/1529-0131(200012)43:12<2793::AID-ANR20>3.0.CO;2-6.CrossRefPubMed
34.
Brown EE, Edberg JC, Kimberly RP: Fc receptor genes and the systemic lupus erythematosus diathesis. Autoimmunity. 2007, 40: 567-581. 10.1080/08916930701763710.CrossRefPubMed
35.
Li X, Wu J, Carter RH, Edberg JC, Su K, Cooper GS, Kimberly RP: A novel polymorphism in the Fcγ receptor IIB (CD32B) transmembrane region alters receptor signaling. Arthritis Rheum. 2003, 48: 3242-3252. 10.1002/art.11313.CrossRefPubMed
36.
Floto RA, Clatworthy MR, Heilbronn KR, Rosner DR, MacAry PA, Rankin A, Lehner PJ, Ouwehand WH, Allen JM, Watkins NA, Smith KG: Loss of function of a lupus-associated FcγRIIb polymorphism through exclusion from lipid rafts. Nat Med. 2005, 11: 1056-1058. 10.1038/nm1288.CrossRefPubMed
37.
Su K, Yang H, Li X, Gibson AW, Cafardi JM, Zhou T, Edberg JC, Kimberly RP: Expression profile of FcγRIIb on leukocytes and its dysregulation in systemic lupus erythematosus. J Immunol. 2007, 178: 3272-3280.PubMedCentralCrossRefPubMed
38.
Mozo L, Suarez A, Gutierrez C: Glucocorticoids up-regulate constitutive interleukin-10 production by human monocytes. Clin Exp Allergy. 2004, 34: 406-412. 10.1111/j.1365-2222.2004.01824.x.CrossRefPubMed
39.
Garrelds IM, van Hal PT, Haakmat RC, Hoogsteden HC, Saxena PR, Zijlstra FJ: Time dependent production of cytokines and eicosanoids by human monocytic leukaemia U937 cells; effects of glucocorticosteroids. Mediators Inflamm. 1999, 8: 229-235. 10.1080/09629359990397.PubMedCentralCrossRefPubMed
40.
Llorente L, Richaud-Patin Y, Wijdenes J, Alcocer-Varela J, Maillot MC, Durand-Gasselin I, Fourrier BM, Galanaud P, Emilie D: Spontaneous production of interleukin-10 by B lymphocytes and monocytes in systemic lupus erythematosus. Eur Cytokine Netw. 1993, 4: 421-427.PubMed
41.
Xia CQ, Peng R, Beato F, Clare-Salzler MJ: Dexamethasone induces IL-10-producing monocyte-derived dendritic cells with durable immaturity. Scand J Immunol. 2005, 62: 45-54. 10.1111/j.1365-3083.2005.01640.x.CrossRefPubMed
42.
Haas C, Ryffel B, Le Hir M: IFN-γ is essential for the development of autoimmune glomerulonephritis in MRL/Ipr mice. J Immunol. 1997, 158: 5484-5491.PubMed
43.
Calvani N, Satoh M, Croker BP, Reeves WH, Richards HB: Nephritogenic autoantibodies but absence of nephritis in Il-12p35-deficient mice with pristane-induced lupus. Kidney Int. 2003, 64: 897-905. 10.1046/j.1523-1755.2003.00178.x.CrossRefPubMed
44.
Nacionales DC, Kelly-Scumpia KM, Lee PY, Weinstein JS, Lyons R, Sobel E, Satoh M, Reeves WH: Deficiency of the type I interferon receptor protects mice from experimental lupus. Arthritis Rheum. 2007, 56: 3770-3783. 10.1002/art.23023.PubMedCentralCrossRefPubMed
45.
Uhm WS, Na K, Song GW, Jung SS, Lee T, Park MH, Yoo DH: Cytokine balance in kidney tissue from lupus nephritis patients. Rheumatology (Oxford). 2003, 42: 935-938. 10.1093/rheumatology/keg255.CrossRef
46.
Peterson KS, Huang JF, Zhu J, D'Agati V, Liu X, Miller N, Erlander MG, Jackson MR, Winchester RJ: Characterization of heterogeneity in the molecular pathogenesis of lupus nephritis from transcriptional profiles of laser-captured glomeruli. J Clin Invest. 2004, 113: 1722-1733.PubMedCentralCrossRefPubMed
47.
Zhuang H, Narain S, Sobel E, Lee PY, Nacionales DC, Kelly KM, Richards HB, Segal M, Stewart C, Satoh M, Reeves WH: Association of anti-nucleoprotein autoantibodies with upregulation of type I interferon-inducible gene transcripts and dendritic cell maturation in systemic lupus erythematosus. Clin Immunol. 2005, 117: 238-250. 10.1016/j.clim.2005.07.009.CrossRefPubMed
48.
Heller T, Gessner JE, Schmidt RE, Klos A, Bautsch W, Kohl J: Cutting edge: Fc receptor type I for IgG on macrophages and complement mediate the inflammatory response in immune complex peritonitis. J Immunol. 1999, 162: 5657-5661.PubMed
49.
Saito T, Yusa A, Soma J, Ootaka T, Sato H, Ito S: Significance of leukocyte infiltration in membranous nephropathy with segmental glomerulosclerosis. Nephron. 1998, 80: 414-420. 10.1159/000045213.CrossRefPubMed
50.
Yang N, Isbel NM, Nikolic-Paterson DJ, Li Y, Ye R, Atkins RC, Lan HY: Local macrophage proliferation in human glomerulonephritis. Kidney Int. 1998, 54: 143-151. 10.1046/j.1523-1755.1998.00978.x.CrossRefPubMed
51.
Weidner S, Carl M, Riess R, Rupprecht HD: Histologic analysis of renal leukocyte infiltration in antineutrophil cytoplasmic antibody-associated vasculitis: importance of monocyte and neutrophil infiltration in tissue damage. Arthritis Rheum. 2004, 50: 3651-3657. 10.1002/art.20607.CrossRefPubMed
52.
Clynes R, Maizes JS, Guinamard R, Ono M, Takai T, Ravetch JV: Modulation of immune complex-induced inflammation in vivo by the coordinate expression of activation and inhibitory Fc receptors. J Exp Med. 1999, 189: 179-185. 10.1084/jem.189.1.179.PubMedCentralCrossRefPubMed
Metadata
Title
Increased expression of FcγRI/CD64 on circulating monocytes parallels ongoing inflammation and nephritis in lupus
Authors
Yi Li
Pui Y Lee
Eric S Sobel
Sonali Narain
Minoru Satoh
Mark S Segal
Westley H Reeves
Hanno B Richards
Publication date
01-02-2009
Publisher
BioMed Central
Published in
Arthritis Research & Therapy / Issue 1/2009
Electronic ISSN: 1478-6362
DOI
https://doi.org/10.1186/ar2590

Other articles of this Issue 1/2009

Arthritis Research & Therapy 1/2009 Go to the issue

Research article

Impaired vascular responses to parasympathetic nerve stimulation and muscarinic receptor activation in the submandibular gland in nonobese diabetic mice

Review

Psoriatic arthritis: from pathogenesis to therapy

Review

Developments in the clinical understanding of rheumatoid arthritis

Research article

The response to oestrogen deprivation of the cartilage collagen degradation marker, CTX-II, is unique compared with other markers of collagen turnover

Research article

Medication persistence over 2 years of follow-up in a cohort of early rheumatoid arthritis patients: associated factors and relationship with disease activity and with disability

Research article

The proliferative human monocyte subpopulation contains osteoclast precursors
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits